Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lineage Cell Therapeutics (LCTX) Return on Assets (2016 - 2025)

Lineage Cell Therapeutics' Return on Assets history spans 15 years, with the latest figure at 0.35% for Q4 2025.

  • For Q4 2025, Return on Assets fell 17.0% year-over-year to 0.35%; the TTM value through Dec 2025 reached 0.35%, down 17.0%, while the annual FY2025 figure was 0.56%, 39.0% down from the prior year.
  • Return on Assets reached 0.35% in Q4 2025 per LCTX's latest filing, up from 0.35% in the prior quarter.
  • In the past five years, Return on Assets ranged from a high of 0.1% in Q3 2021 to a low of 0.36% in Q3 2022.
  • Average Return on Assets over 5 years is 0.23%, with a median of 0.21% recorded in 2023.
  • Peak YoY movement for Return on Assets: increased 29bps in 2021, then decreased -26bps in 2022.
  • A 5-year view of Return on Assets shows it stood at 0.28% in 2021, then grew by 25bps to 0.21% in 2022, then dropped by 0bps to 0.21% in 2023, then increased by 15bps to 0.18% in 2024, then tumbled by -95bps to 0.35% in 2025.
  • Per Business Quant, the three most recent readings for LCTX's Return on Assets are 0.35% (Q4 2025), 0.35% (Q3 2025), and 0.31% (Q2 2025).